Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

  • 2006-05-24
  • European Journal of Clinical Nutrition 60(11)
    • C. Larsen
    • Susanne Dorthe Nielsen
    • P. Kæstel
    • Elke Brockmann
    • M. Bennedsen
    • Hanne Risager Christensen
    • D. Eskesen
    • B. Jacobsen
    • Kim F. Michaelsen

Abstract

Objective: This study was performed to investigate the dose-response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10(10) CFU/day probiotic and placebo group.

Design: The study was designed as a randomized, placebo-controlled, double-blinded, parallel dose-response study.

Subjects: Healthy young adults (18-40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18-40 years)) completed the study.

Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10(8), 10(9), 10(10) or 10(11) CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention.

Results: The fecal recovery of BB-12 increased significantly (P < 0.001) with increasing dose. In the group receiving 10(11) CFU/day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P = 0.018) was observed. No overall dose-response effect was found on the blood lipids. High doses of probiotics were well tolerated.

Conclusion: A dose-related recovery of BB-12 from feces was observed.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactisImproved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactisRecovery of BB-12 from FecesBeneficial
Large
Bifidobacterium animalis subsp. lactis B420Increased Stool LoosenessNeutral
Moderate
Bifidobacterium animalis subsp. lactis B420Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium animalis subsp. lactis BLC1Improved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactis BLC1Increased TolerabilityBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BLC1No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium animalis subsp. lactis BLC1No Change in Lipid ProfileNeutral
Small
Bifidobacterium animalis subsp. lactis BLC1Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium animalis subsp. lactis BS-01Improved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactis BS-01No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium animalis subsp. lactis BS-01No Change in Serum Lipid LevelsNeutral
Small
Bifidobacterium animalis subsp. lactis BS-01Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium animalis subsp. lactis CECT 8145Improved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactis CECT 8145Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium animalis subsp. lactis LAFTI B94Improved Lipid ProfileNeutral
Small
Bifidobacterium animalis subsp. lactis LAFTI B94Improved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactis LAFTI B94Increased Colonization by Beneficial Bacteria (Bifidobacterium animalis subsp. lactis BB-12)Beneficial
Large
Bifidobacterium animalis subsp. lactis VK2Improved Stool ConsistencyNeutral
Small
Bifidobacterium animalis subsp. lactis VK2Increased Fecal Recovery of Bifidobacterium Animalis Subsp LactisNeutral
Large
Bifidobacterium bifidum BB01Increased Probiotic ToleranceNeutral
Moderate
Bifidobacterium bifidum BB01No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium bifidum BB01No Change in Lipid ProfileNeutral
Small
Bifidobacterium bifidum BB01Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium bifidum BB01Reduced Stool ConsistencyNeutral
Moderate
Bifidobacterium bifidum Bb-02Improved Stool ConsistencyNeutral
Small
Bifidobacterium bifidum Bb-02Improved Tolerance to High Doses of ProbioticsNeutral
Moderate
Bifidobacterium bifidum Bb-02No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium bifidum Bb-02No Change in Lipid ProfileNeutral
Small
Bifidobacterium bifidum Bb-02Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium bifidum/lactis Bb-02Increased Persistence of Probiotics in Fecal MatterNeutral
Moderate
Bifidobacterium bifidum/lactis Bb-02Increased Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis B420Increased Fecal Recovery of Bifidobacterium Animalis Subsp LactisNeutral
Large
Bifidobacterium lactis B420No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium lactis B420No Change in Lipid ProfileNeutral
Small
Bifidobacterium lactis B420Reduced Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis Bb-02Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium lactis Bb-02Reduced Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis BB-12Increased Dose ToleranceNeutral
Large
Bifidobacterium lactis BB-12No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium lactis BB-12No Change in Serum Lipid LevelsNeutral
Small
Bifidobacterium lactis BB-12Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium lactis BB-12Reduced Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis Bi-07Increased Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis Bi-07No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium lactis Bi-07No Change in Lipid ProfileNeutral
Small
Bifidobacterium lactis Bi-07Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium lactis BLC-1Good TolerabilityBeneficial
Large
Bifidobacterium lactis BLC-1Improved Stool ConsistencyNeutral
Small
Bifidobacterium lactis BLC-1No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium lactis BLC-1No Change in Serum Lipid LevelsNeutral
Small
Bifidobacterium lactis BLC-1Recovery of BB-12 from FecesBeneficial
Large
Bifidobacterium lactis UABla-12Increased Stool ConsistencyNeutral
Moderate
Bifidobacterium lactis UABla-12No Change in Fecal Bacterial CompositionNeutral
Small
Bifidobacterium lactis UABla-12No Change in Serum Lipid LevelsNeutral
Small
Bifidobacterium lactis UABla-12Recovery of BB-12 from FecesBeneficial
Large
Lactobacillus paracasei 431Altered Fecal Bacterial CompositionNeutral
Small
Lactobacillus paracasei 431Increased Persistence of Probiotics in Fecal MatterNeutral
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.